No matter what happens with stock prices or the economy, one thing is certain... Companies (and individuals) will never stop conducting the necessary research...
Cybin, a biopharmaceutical company focused on progressing Psychedelics to Therapeutics outlined its upcoming priorities and near-term milestones that...
The article 2022 End of Year Review: Cybin was originally published on Microdose. The end of the year is a convenient time to look back and...
The article Tripping Without The Trip: Non-Hallucinogenic Psychedelics was originally published on Microdose. Do non-hallucinogenic psychedelic experiences...
The article Wonderland Journal: A New Generation of Psychedelic Community & Technology was originally published on Microdose. In 1967, Timothy Leary...
You may have never heard of psilacetin. In fact, when you first saw it, it may have confused you. “Is this a misspelling of psilocybin? Is...
Cybin Inc. (NEO:CYBN | NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the...
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today reported unaudited...
UNIFY founder Adil Kassam discusses how technology coupled with global group meditation can facilitate synchronized transformational experiences among...
Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics®”, today announced the...